Aggredyne Names Two New Directors

HOUSTON--(BUSINESS WIRE)--Brady F. Carruth, president of the Wortham Foundation, and Edgar C. “Red” Griffin, founder of Grifco Transportation, have joined the Aggredyne, Inc., board of directors. Aggredyne (www.aggredyne.com) is a Houston-based biomedical diagnostics company that is defining a new standard for platelet function testing.

“Our work together at the Houston Livestock Show and Rodeo showed me how Brady’s business acumen and Red’s achievement-based mindset could benefit Aggredyne, even though it is in a different business sector.”

Mr. Carruth has been a director of two NYSE-listed companies and is experienced in acquisitions and operation of distribution and service businesses. He acquired London American Risk Specialists, Inc., in 2002 and remains a director and equity partner.

Mr. Griffin, as chairman and president, grew Coastal Towing Inc. into the largest transporter of heavy marine liquid fuel oil on the inland waterways of the United States before selling the company. He then started Grifco Transportation, Ltd., grew it in seven years from zero assets to 20 tank barges and 10 towboats, and sold it for $125 million to an NYSE-listed company.

Aggredyne Chairman & CEO Dr. Ed Teitel said, “We are fortunate to be able to attract such high caliber talent to Aggredyne. Their experience both as board members in public and private companies and as successful entrepreneurs will help advance our early-stage company to the next level.”

According to Aggredyne President & COO Robert Hux, both men are also active in giving back to their communities. “Our work together at the Houston Livestock Show and Rodeo showed me how Brady’s business acumen and Red’s achievement-based mindset could benefit Aggredyne, even though it is in a different business sector.”

ABOUT AGGREDYNE, INC.

Aggredyne, Inc. (www.aggredyne.com) is a biomedical company founded in early 2011 to commercialize the AggreGuide^TM platelet function analyzer. The AggreGuide system is an in-vitro diagnostic test that measures how sticky a patient’s platelets are and how well the patient is responding to antiplatelet medications such as aspirin, Plavix® (clopidogrel), Effient® (prasugrel) and Brilinta® (ticagrelor).

Plavix is a registered trademark of Sanofi.
Effient is a registered trademark of Eli Lilly and Company.
Brilinta is a trademark of the AstraZeneca group of companies.